Symons Capital Management Inc. purchased a new position in shares of Bristol-Myers Squibb Co (NYSE:BMY) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 107,817 shares of the biopharmaceutical company’s stock, valued at approximately $5,603,000. Bristol-Myers Squibb accounts for approximately 2.3% of Symons Capital Management Inc.’s portfolio, making the stock its 16th biggest holding.
Several other hedge funds have also recently bought and sold shares of the company. Trust Co. of Virginia VA lifted its holdings in Bristol-Myers Squibb by 105.7% during the 4th quarter. Trust Co. of Virginia VA now owns 50,048 shares of the biopharmaceutical company’s stock worth $2,601,000 after purchasing an additional 25,712 shares in the last quarter. Savant Capital LLC lifted its holdings in Bristol-Myers Squibb by 7.3% during the 4th quarter. Savant Capital LLC now owns 11,523 shares of the biopharmaceutical company’s stock worth $599,000 after purchasing an additional 781 shares in the last quarter. Highwater Wealth Management LLC purchased a new stake in Bristol-Myers Squibb during the 4th quarter worth about $170,000. Hollencrest Capital Management lifted its holdings in Bristol-Myers Squibb by 176.1% during the 4th quarter. Hollencrest Capital Management now owns 9,604 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 6,126 shares in the last quarter. Finally, Northern Capital Management LLC purchased a new stake in Bristol-Myers Squibb during the 4th quarter worth about $3,907,000. Institutional investors own 73.14% of the company’s stock.
BMY has been the topic of a number of recent research reports. William Blair reissued an “outperform” rating on shares of Bristol-Myers Squibb in a report on Tuesday, November 27th. BMO Capital Markets dropped their price objective on Bristol-Myers Squibb to $56.00 and set a “market perform” rating on the stock in a report on Tuesday, November 27th. ValuEngine raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Friday, December 7th. Credit Suisse Group reissued a “hold” rating and set a $59.00 price objective on shares of Bristol-Myers Squibb in a report on Thursday, December 13th. Finally, Morgan Stanley set a $54.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Thursday, December 20th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $59.13.
NYSE:BMY opened at $48.16 on Friday. Bristol-Myers Squibb Co has a twelve month low of $44.30 and a twelve month high of $64.05. The stock has a market capitalization of $78.63 billion, a price-to-earnings ratio of 12.10, a price-to-earnings-growth ratio of 2.46 and a beta of 0.81. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.50 and a current ratio of 1.61.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a return on equity of 48.99% and a net margin of 21.95%. The firm had revenue of $5.97 billion for the quarter, compared to analysts’ expectations of $5.95 billion. During the same quarter last year, the firm posted $0.68 EPS. The company’s revenue was up 9.6% compared to the same quarter last year. As a group, research analysts expect that Bristol-Myers Squibb Co will post 4.15 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a $0.41 dividend. The ex-dividend date is Thursday, April 4th. This represents a $1.64 annualized dividend and a dividend yield of 3.41%. Bristol-Myers Squibb’s payout ratio is currently 41.21%.
COPYRIGHT VIOLATION WARNING: “Symons Capital Management Inc. Purchases New Position in Bristol-Myers Squibb Co (BMY)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2019/03/24/symons-capital-management-inc-purchases-new-position-in-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Story: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.